Viva Biotech Holdings (OTCMKTS:VBIZF) Short Interest Update

Viva Biotech Holdings (OTCMKTS:VBIZFGet Rating) was the recipient of a large drop in short interest during the month of July. As of July 15th, there was short interest totalling 3,330,700 shares, a drop of 26.7% from the June 30th total of 4,543,700 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Viva Biotech Stock Down 3.4 %

Shares of Viva Biotech stock opened at $0.22 on Monday. Viva Biotech has a 52 week low of $0.01 and a 52 week high of $1.30. The company has a 50 day moving average price of $0.34 and a 200 day moving average price of $0.39.

Viva Biotech Company Profile

(Get Rating)

Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure determination of protein, and SPR technology.

Read More

Want More Great Investing Ideas?

Receive News & Ratings for Viva Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viva Biotech and related companies with MarketBeat.com's FREE daily email newsletter.